Samuel Dubé

MD, FRCSC, Gynécologue oncologue #CHUM #UdeM 👨🏽‍⚕️ Spécialiste en onco-gériatrie 👵🏻 (former Geri Onc Fellow at #UofT) Fier Bas St-Laurentien 👨🏽‍🌾

[Samuel Dubé @DrSamDube]

@monsefderraji Ces données sont en effet préoccupantes pour la MD fam. J’ai beaucoup de respect pour ce que vous faites. Or, pour le poste neurochirurgie, il s’agit d’un contingent particulier, donc je ne pense pas qu’il faut tirer de conclusions de cette donnée https://t.co/kyhOFhobGf

[Samuel Dubé @DrSamDube]

Je vous recommande cet article de La Presse : Les enfants en soins palliatifs ne sont pas des statistiques https://t.co/t30rD2MmQE

[Samuel Dubé @DrSamDube]

@Consultgratuite On dirait

[Dr Rishabh Jain @DrRishabhOnco]

🚨 ONS/ASCO Guideline 2025: Antineoplastic Extravasation 💉🔥

🧾 JCO Oncol Pract | Thomas et al.

🔑 Key Recs:

1️⃣ Antidotes
 • Dexrazoxane → Anthracyclines
 • Hyaluronidase → Vinca, Paclitaxel/Docetaxel
 • DMSO → Mitomycin, Mitoxantrone (or anthracyclines if no dexrazoxane)
 • Sodium thiosulfate → Cisplatin (>0.5 mg/mL, >20 mL), Bendamustine

2️⃣ Thermal compresses
 • ❄ Cold → Anthracyclines, alkylators (except oxaliplatin), antimetabolites
 • 🔥 Warm → Vinca, etoposide, oxaliplatin, taxanes (+hyaluronidase)
 • ⏱ Longer duration (>24h) preferred

3️⃣ Central line extravasation → early surgical referral/escalation

💡 Goal: tissue preservation, ↓ necrosis, avoid hospital/surgery, prevent chemo delays.

📖 Thomas T, Clark C, Backler C, et al. JCO Oncol Pract. 2025.
🔗DOI: https://t.co/qDc3bLs606

#OncoTwitter #MedTwitter #Nursing #PatientSafety
@OncoAlert @ASCO @myESMO

[Dr Rishabh Jain @DrRishabhOnco]

🤔 Is IMRT making cisplatin obsolete in early cervical cancer?

📖 Ann Oncol 2025 | Phase III | NRG/GOG-263 + KGOG1008 | n=340 (316 eligible)

👩‍🦰 Stage I–IIA, post radical hysterectomy + pelvic LND (Sedlis intermediate-risk)

🆚 Trial arms:

🔵 RT alone → 50.4 Gy/28 fx (3D-CRT/IMRT)
🟣 CRT → RT ➕ 💉 cisplatin 40 mg/m² weekly ×6

📊 Key results (median FU 76.5 mo):

📌 3-yr RFS: 85.4% (RT) vs 88.5% (CRT) → HR 0.70 (NS)

📌 OS: HR 0.59 (NS)

⚠️ Grade ≥3 AEs: 15.3% (RT) vs 🚨 42.9% (CRT) — neutropenia/leukopenia

❤️‍🩹 QoL: dip with CRT ➡️ recovery by ~36 wks

🔍 Exploratory: CRT favored with 3D-CRT, not with IMRT

✨ Takeaway:
Cisplatin did not significantly improve RFS/OS ❌ but caused more toxicity 🚑.

👉 With modern IMRT, RT alone may be enough for many intermediate-risk pts.

🔖 Ryu SY, Deng W, Albuquerque K, et al. Ann Oncol. 2025.
🔗DOI: https://t.co/ylAAvryQje

#OncoTwitter #MedTwitter #CervicalCancer #GynOnc
@OncoAlert @myesmo @asco @AnnOncology

[Enrique Soto @EnriqueSoto8]

📖 Looking for a good weekend read? Check out the new @ASCO Global Geriatric Oncology Guidelines #gerionc #globonc.
They provide practical, resource-stratified recommendations to improve care for older adults with cancer worldwide. 🌍👵👴
🔗 https://t.co/bQpp9DkGWg

[Enrique Soto @EnriqueSoto8]

🎧 Listen to the ASCO Guidelines Podcast where we talk about our new Global Geriatric Oncology Guidelines 🌍👵🧓
We discuss why these recommendations matter and how they can improve cancer care for older adults worldwide.
Listen here 👉 https://t.co/oR65wE0ZVF
#gerionc #globonc

[NEJM @NEJM]

In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results and Research Summary: https://t.co/yrL8mtlmvd

[Enrique Soto @EnriqueSoto8]

Thrilled to share our new ASCO Global Guideline on Geriatric Assessment 🌍👵👴 — supporting cancer care for older adults in resource-constrained settings.
Published in @JCOGlobalOncol ➡️ https://t.co/bQpp9DleLO
#gerionc #globonc @ASCO

[Julie Hallet @HalletJulie]

🆕🧰HOMECARE - for older adults after cancer surgery

🏠Immediate (1 month) & chronic homecare (7–12 months)
📊Strong performance & well-calibrated

For help with risk communication & preop preparatio🤝

Online calculator coming!🧮

https://t.co/bmOKopeQ3C

[Nicholas Fabiano, MD @NTFabiano]

This is the Atlas of Cognitive Disorders

[Enrique Soto @EnriqueSoto8]

Older adults aged 65-75 were less likely to have treatment modifications after the geriatric assessment as reported by Dr Alibhai in #MASCC2025

[Journal of Geriatric Oncology @JGeriOnc]

Impact of geriatric assessment on decision-making for adjuvant chemotherapy in older patients with breast cancer https://t.co/AYyapi0eQ4 @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[Praveen Kumar Marimuthu @drmpk91]

💥 INTERLACE ticks all the right boxes:
OS ✅ Toxicity ✅ QoL ✅
🧪 Adding induction chemo (IC) before CRT showed an 8% absolute OS benefit at 5 yrs —with a manageable 10% ↑ in grade 3/4 AEs.
But what about QOL? 🤔
No significant QoL drop with IC vs CRT alone, says this substudy https://t.co/gaGqvaeG6M
💪 Survival gain without QoL pain
#GynOnc #GynCSM

[Samuel Dubé @DrSamDube]

@StephanieChamMD @gynoncjnls @LWalterMD @AmanikaKumar @smlichtman_md Very nice paper! Congrats :)

[Stephanie Cham, MD @StephanieChamMD]

Thank you to @gynoncjnls for publishing our invited review article on frailty and optimizing patient-centered care for our older adult patients! https://t.co/lNXDs0iWwy

[IJGC @IJGConline]

#2025SpecialIssue Controversies in the management of serous tubal intra-epithelial carcinoma lesions of the #fallopiantube

✅ https://t.co/oXed8xWeav

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @thomasbartlMD @kfischermd @claritasantia @stephjeangill @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelissen

[OncoAlert @OncoAlert]

Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG)

#CancerHasNoAge 🚨
https://t.co/0L7Mdtmafj

Immune checkpoint inhibitors (ICIs) have significantly improved cancer treatment, particularly for older adults, a rapidly growing demographic often prescribed these therapies. However, managing ICI-related toxicities in older adults, especially those with frailty and comorbidities, presents unique challenges. This Policy Review, developed by the International Society of Geriatric Oncology (SIOG), provides an evidence-based framework for healthcare providers, caregivers, and policymakers, addressing specific considerations for older adults that are not sufficiently covered by existing guidelines, while integrating geriatric oncology principles into the treatment approach. #GeriOnc #Immunotherapy

@CEochagain
@neuendorff_nr
@jleipy
@martheverhaert
@NienkedeGlas
@kgsindhu
@FabioGomes_Go
@Decoster_Lore
@SRostoft
@nicolobattisti

#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

Ping GeriOnc Faculty
@WilliamDale_MD @IshwariaMD @drcbsteer @ravikanesvaran @crisbergerot

[AJOG @AJOG_thegray]

Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks - Forest plot for overall mortality https://t.co/ITPmIopd5A